XNASBSGM
Market cap25mUSD
Dec 24, Last price
1.48USD
1D
-0.67%
1Q
337.09%
IPO
-97.78%
Name
BioSig Technologies Inc
Chart & Performance
P/E
—
P/S
1,417.09
EPS
—
Div Yield, %
0.04%
Shrs. gr., 5y
38.35%
Rev. gr., 5y
%
Revenues
18k
-93.71%
Net income
-29m
L+6.49%
CFO
-17m
L-20.23%
Earnings
May 19, 2025
Profile
BioSig Technologies, Inc., together with its subsidiaries, operates as medical device company. The company's proprietary product includes precise uninterrupted real-time evaluation of electrograms electrophysiology (PURE EP) system, a signal processing platform that combines hardware and software to address known challenges associated to signal acquisition that enables electrophysiologists to see signals and analyze in real-time. It also focuses on enhancing intracardiac signal acquisition and diagnostic information for the procedures of atrial fibrillation, as well as is designed to address long-standing limitations that slow and disrupt cardiac catheter ablation procedures. The company has a research agreement with University of Minnesota to develop novel therapies to treat sympathetic nervous system diseases; and a strategic collaboration with the Mayo Foundation for Medical Education and Research to develop an AI-and machine learning software solution for PURE EP systems. BioSig Technologies, Inc. was incorporated in 2009 and is headquartered in Westport, Connecticut.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | 2014‑12 | |
| Income | ||||||||||
Revenues | 18 -93.71% | 286 -35.15% | 441 | |||||||
Cost of revenue | 28,169 | 27,258 | 33,654 | |||||||
Unusual Expense (Income) | ||||||||||
NOPBT | (28,151) | (26,972) | (33,213) | |||||||
NOPBT Margin | ||||||||||
Operating Taxes | 9 | (1,494) | ||||||||
Tax Rate | ||||||||||
NOPAT | (28,151) | (26,981) | (31,719) | |||||||
Net income | (29,041) 6.49% | (27,271) -13.04% | (31,362) -39.89% | |||||||
Dividends | (9) | (9) | (9) | |||||||
Dividend yield | 0.03% | 0.05% | 0.01% | |||||||
Proceeds from repurchase of equity | 15,361 | 10,353 | 10,304 | |||||||
BB yield | -43.99% | -57.23% | -13.79% | |||||||
| Debt | ||||||||||
Debt current | 698 | 313 | 283 | |||||||
Long-term debt | 555 | 1,217 | 1,029 | |||||||
Deferred revenue | 5 | |||||||||
Other long-term liabilities | 5 | |||||||||
Net debt | 1,063 | 1,173 | (10,347) | |||||||
| Cash flow | ||||||||||
Cash from operating activities | (17,313) | (21,705) | (26,399) | |||||||
CAPEX | (186) | (168) | (542) | |||||||
Cash from investing activities | (186) | (168) | (542) | |||||||
Cash from financing activities | 17,332 | 10,571 | 10,332 | |||||||
FCF | (26,285) | (25,070) | (32,380) | |||||||
| Balance | ||||||||||
Cash | 190 | 458 | 11,659 | |||||||
Long term investments | (101) | |||||||||
Excess cash | 189 | 343 | 11,637 | |||||||
Stockholders' equity | (244,875) | (215,835) | (188,562) | |||||||
Invested Capital | 242,789 | 216,997 | 201,793 | |||||||
ROIC | ||||||||||
ROCE | 1,349.52% | |||||||||
| EV | ||||||||||
Common stock shares outstanding | 7,352 | 4,307 | 3,351 | |||||||
Price | 4.75 13.10% | 4.20 -81.17% | 22.30 -42.82% | |||||||
Market cap | 34,921 93.04% | 18,090 -75.79% | 74,732 -31.34% | |||||||
EV | 36,115 | 19,347 | 64,709 | |||||||
EBITDA | (27,790) | (26,679) | (33,015) | |||||||
EV/EBITDA | ||||||||||
Interest | 3 | |||||||||
Interest/NOPBT | ||||||||||